Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGA111 in Degenerative Disc Disease Undergoing Lumbar Interbody Fusion
NCT06115512Phase 3Terminated
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in degenerative disc disease (DDD) comparing AGA111 with Placebo (2 arms). Primary endpoint: Overall success rate at 52 weeks. Started Dec 2023; status: terminated.
02
Drugs
AGA111
03
Conditions
degenerative disc disease (DDD)
Beyond the preview
Go deeper on NCT06115512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115512.